泰林生物(300813) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥48,043,207.85, representing a 17.88% increase compared to ¥40,755,733.60 in the same period last year[9] - Net profit attributable to shareholders was ¥9,598,366.31, up 30.64% from ¥7,347,252.02 year-on-year[9] - The net profit after deducting non-recurring gains and losses increased by 75.94%, reaching ¥9,101,615.73 compared to ¥5,172,996.49 in the previous year[9] - Basic and diluted earnings per share increased by 20.00%, reaching ¥0.18 per share compared to ¥0.15 per share in the previous year[9] - Total profit reached 10.90 million yuan, an increase of 30.79% compared to the same period last year[20] - Net profit attributable to shareholders was 9.60 million yuan, up 30.63% year-on-year[20] - The company reported a total comprehensive income of ¥9,598,366.31 for the quarter, up from ¥7,347,252.02 in the prior year[45] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net outflow of ¥11,806,521.67 compared to a net inflow of ¥16,536,884.40 in the same period last year, marking a -171.40% change[9] - Operating cash inflow totaled CNY 63,240,845.86, down from CNY 67,774,562.34 year-over-year[52] - Net cash flow from operating activities was negative CNY 11,806,521.67, a significant decline from a positive CNY 16,536,884.40 in the previous year[52] - Cash flow from investment activities showed a net outflow of CNY 150,032,262.15, compared to a net outflow of CNY 56,825,288.47 in the prior period[52] - The company reported a cash inflow from financing activities of CNY 12,000,000.00, down from CNY 213,100,000.00 in the previous period[56] - The net increase in cash and cash equivalents was negative CNY 162,455,536.28, contrasting with a positive increase of CNY 161,865,587.76 in the prior year[53] Assets and Liabilities - Total assets at the end of the reporting period were ¥546,712,591.66, a 1.24% increase from ¥539,993,675.87 at the end of the previous year[9] - The company's net assets attributable to shareholders increased by 2.16%, amounting to ¥453,843,050.81 compared to ¥444,244,684.50 at the end of the previous year[9] - Total liabilities increased to ¥66,730,657.28 from ¥51,652,561.29, indicating a rise of approximately 29.2%[43] - The total liabilities decreased to CNY 92,869,540.85 from CNY 95,748,991.37, a reduction of about 3.1%[36] - The company's equity attributable to shareholders rose to CNY 453,843,050.81 from CNY 444,244,684.50, marking an increase of approximately 2.2%[37] Operational Highlights - The company completed structural improvements on the cell preparation workstation and validated the performance of a new type of bacterial collection instrument[20] - The top five suppliers changed, with no significant reliance on a few suppliers, indicating a stable supply chain[22] - The top five customers also changed, reflecting a shift in demand as the impact of the pandemic decreased[22] - The company invested a total of 197.94 million yuan in fundraising projects, with 65.61% of the planned investment completed by the end of the reporting period[26] Expenses and Payments - Financial expenses rose by 86.88% to -¥1,783,251.30, driven by increased interest and bank investment income[18] - Research and development expenses for Q1 2021 were ¥9,286,741.64, compared to ¥8,652,529.22 in the previous year, indicating a year-over-year increase of about 7.3%[43] - Tax payments increased by 83.10% to approximately 11.43 million yuan due to higher VAT and corporate income tax payments[21] - The company reported a 50.47% increase in cash paid to employees, totaling approximately 26.93 million yuan[21] Inventory and Receivables - Inventory increased significantly to CNY 81,265,369.21 from CNY 63,193,535.61, representing a growth of approximately 28.6%[34] - Accounts receivable increased to CNY 18,189,447.49 from CNY 17,874,328.92, showing a growth of about 1.8%[34] - Other receivables increased by 68.25% to ¥4,905,028.85 due to increased prepayments for convertible bond project sponsorship fees[16] Compliance and Governance - The company has no reported non-operating fund occupation by controlling shareholders or related parties during the reporting period[29] - There were no violations regarding external guarantees during the reporting period[28]